While Retatrutide remains investigational, eligible patients may be able to access medical weight loss options that are currently available through provider-supervised programs
BPC-157 has one of the largest preclinical literatures of any research peptide, spanning more than three decades, while human evidence remains limited to early-phase and pilot work
PMID 9456470 Westrin A, Ekman R, Traskman-Bendz L (1998)
The trans-3-hexenoyl group on the N-terminal tyrosine acts as a protective cap against dipeptidyl peptidase-IV (DPP-IV), the enzyme that cleaves native GHRH between residues 2 and 3 and generates the short plasma half-life that limits unmodified GHRH activity
The final word on BPC-157 has yet to be written.
But if the Leydig cells have been dormant throughout a long suppressive cycle, even restored LH signalling produces a blunted testosterone response from atrophied and desensitised testes